MX2016012558A - Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo. - Google Patents
Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo.Info
- Publication number
- MX2016012558A MX2016012558A MX2016012558A MX2016012558A MX2016012558A MX 2016012558 A MX2016012558 A MX 2016012558A MX 2016012558 A MX2016012558 A MX 2016012558A MX 2016012558 A MX2016012558 A MX 2016012558A MX 2016012558 A MX2016012558 A MX 2016012558A
- Authority
- MX
- Mexico
- Prior art keywords
- cardiac dysfunction
- heart failure
- congestive heart
- urocortin
- virus vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
Abstract
En modalidades alternativas, se proporcionan métodos para tratar, aminorar o proteger (prevenir) la falla de corazón congestivo (CHF) o una disfunción cardíaca relacionada con diabetes, que comprende: proporcionar un ácido nucleico transcripto o mensaje, o gen que codifica urocortina 2 y/o que codifica urocortina 3, operativamente enlazado a una secuencia regulatoria transcripcional, opcionalmente contenido en un vehículo de expresión o un vector tal como un virus adeno-asociado (AAV), por ejemplo, un serotipo AAV8; y administrar a un individuo o a un paciente en necesidad del mismo, tal como un diabético tipo 2 (T2DM), por ejemplo, mediante administración IV, para de esta manera tratar, aminorar o proteger contra (prevenir) la T2DM y/o la disfunción cardíaca relacionada con diabetes en el individuo o paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461974662P | 2014-04-03 | 2014-04-03 | |
PCT/IB2015/000771 WO2015150914A2 (en) | 2014-04-03 | 2015-04-03 | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016012558A true MX2016012558A (es) | 2017-01-09 |
Family
ID=54241383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016012558A MX2016012558A (es) | 2014-04-03 | 2015-04-03 | Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20160166651A1 (es) |
EP (1) | EP3125948A4 (es) |
JP (1) | JP2017511334A (es) |
KR (1) | KR20160137908A (es) |
CN (1) | CN106456803A (es) |
AU (1) | AU2015242354A1 (es) |
BR (1) | BR112016022854A2 (es) |
CA (1) | CA2943751A1 (es) |
IL (1) | IL248009A0 (es) |
MX (1) | MX2016012558A (es) |
WO (1) | WO2015150914A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL154553A0 (en) * | 2001-03-15 | 2003-09-17 | Res Dev Foundation | Urocortin-iii and uses thereof |
KR20160137908A (ko) * | 2014-04-03 | 2016-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 당뇨병-연관 심기능 장애 및 울혈성 심부전을 치료하기 위한 우로코르틴-2 및 연관 유전자들을 인코딩하는 바이러스 벡터들의 전신 전달 |
EP3337518A4 (en) * | 2015-08-17 | 2019-06-12 | Temple University Of The Commonwealth System Of Higher Education | BAG3 COMPOSITIONS AND METHOD |
JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
WO2018090042A1 (en) * | 2016-11-14 | 2018-05-17 | Renova Therapeutics, Inc. | Methods of treating heart failure |
WO2018090036A1 (en) * | 2016-11-14 | 2018-05-17 | Renova Therapeutics, Inc. | Method of protection for cardiac tissue |
US11760987B2 (en) | 2017-09-07 | 2023-09-19 | The Regents Of The University Of California | Compositions and methods for the treatment or prevention of heart failure |
CN115927398A (zh) * | 2020-07-29 | 2023-04-07 | 舒泰神(北京)生物制药股份有限公司 | 一组肝靶向新型腺相关病毒的获得及其应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5733542A (en) | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
US5270192A (en) | 1991-02-07 | 1993-12-14 | Monsanto Company | Biological artificial liver |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
WO1997016533A1 (en) | 1995-10-31 | 1997-05-09 | The Regents Of The University Of California | Mammalian artificial chromosomes and methods of using same |
WO1997022371A1 (en) | 1995-12-18 | 1997-06-26 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6933331B2 (en) | 1998-05-22 | 2005-08-23 | Nanoproducts Corporation | Nanotechnology for drug delivery, contrast agents and biomedical implants |
US5874268A (en) | 1996-09-23 | 1999-02-23 | Duke University | Method of introducing exogenous compounds into cells by electroporation and apparatus for same |
US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
US20050095227A1 (en) * | 1997-07-22 | 2005-05-05 | The General Hospital Corporation | Treating heart failure |
SE9704076D0 (sv) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilisation of cell structures and use thereof |
US6886568B2 (en) | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US6958212B1 (en) | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
WO2001077328A1 (en) | 2000-04-06 | 2001-10-18 | Franco Wayne P | Methods of using growth factors for treating heart disease |
US7442390B2 (en) | 2000-06-05 | 2008-10-28 | University Of South Florida | Method for enhancing engraftment of cells using mesenchymal progenitor cells |
IL154553A0 (en) * | 2001-03-15 | 2003-09-17 | Res Dev Foundation | Urocortin-iii and uses thereof |
WO2002088332A1 (fr) | 2001-04-24 | 2002-11-07 | Hokkaido Technology Licensing Office Co.,Ltd. | Colonie riche en petites cellules hepatiques, procede d'obtention de cette colonie, procede d'induction de la maturation de cette colonie dans un tissu hepatique et procede d'estimation de l'effet d'un medicament faisant appel a cette colonie riche en petites cellules hepatiques mature |
US7379765B2 (en) | 2003-07-25 | 2008-05-27 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US7166133B2 (en) | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
US20040151766A1 (en) | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
US7241455B2 (en) | 2003-04-08 | 2007-07-10 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent |
US7794706B2 (en) | 2003-10-14 | 2010-09-14 | Medivas, Llc | Bioactive wound dressings and implantable devices and methods of use |
US20050136121A1 (en) | 2003-12-22 | 2005-06-23 | Shear/Kershman Laboratories, Inc. | Oral peptide delivery system with improved bioavailability |
KR20060123384A (ko) | 2003-12-24 | 2006-12-01 | 가부시키가이샤 엘티티 바이오파마 | 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제 |
US7878978B2 (en) * | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
US20070082042A1 (en) | 2004-08-06 | 2007-04-12 | Deok-Hoon Park | Multiple-layered liposome and preparation method thereof |
CA2569736A1 (en) | 2004-08-20 | 2006-03-02 | Russell Anderson | Methods of administering microparticles combined with autologous body components |
EP1796693A2 (en) | 2004-08-26 | 2007-06-20 | Chandrashekhar P. Pathak | Implantable tissue compositions and method |
US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
DE602005025676D1 (de) | 2004-10-18 | 2011-02-10 | Nitto Denko Corp | Intrazelluläre peptidabgabe |
US7759120B2 (en) | 2005-03-02 | 2010-07-20 | Kps Bay Medical, Inc. | Seeding implantable medical devices with cells |
EP1937213B1 (en) | 2005-07-27 | 2017-10-25 | Protiva Biotherapeutics Inc. | Systems and methods for manufacturing liposomes |
CA2580907A1 (en) | 2006-11-21 | 2008-05-21 | The Bionic Ear Institute | Choroid plexus cell implantation to prevent and/or treat hearing loss |
JP5753159B2 (ja) * | 2009-05-05 | 2015-07-22 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 内皮性機能/機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化 |
ES2545794T3 (es) * | 2009-08-28 | 2015-09-15 | Research Development Foundation | Análogos de urocortina 2 y usos de los mismos |
MX2012005262A (es) * | 2009-11-04 | 2012-09-28 | Janssen Pharmaceutica Nv | Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina. |
WO2013123094A2 (en) * | 2012-02-14 | 2013-08-22 | The Regents Of The University Of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
KR20160137908A (ko) * | 2014-04-03 | 2016-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 당뇨병-연관 심기능 장애 및 울혈성 심부전을 치료하기 위한 우로코르틴-2 및 연관 유전자들을 인코딩하는 바이러스 벡터들의 전신 전달 |
-
2015
- 2015-04-03 KR KR1020167030725A patent/KR20160137908A/ko unknown
- 2015-04-03 JP JP2016560507A patent/JP2017511334A/ja active Pending
- 2015-04-03 EP EP15773098.7A patent/EP3125948A4/en not_active Withdrawn
- 2015-04-03 WO PCT/IB2015/000771 patent/WO2015150914A2/en active Application Filing
- 2015-04-03 CA CA2943751A patent/CA2943751A1/en not_active Abandoned
- 2015-04-03 MX MX2016012558A patent/MX2016012558A/es unknown
- 2015-04-03 US US14/678,796 patent/US20160166651A1/en not_active Abandoned
- 2015-04-03 US US15/301,703 patent/US20170182129A1/en not_active Abandoned
- 2015-04-03 CN CN201580026296.7A patent/CN106456803A/zh active Pending
- 2015-04-03 BR BR112016022854A patent/BR112016022854A2/pt not_active Application Discontinuation
- 2015-04-03 AU AU2015242354A patent/AU2015242354A1/en not_active Abandoned
-
2016
- 2016-09-25 IL IL248009A patent/IL248009A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20160166651A1 (en) | 2016-06-16 |
CN106456803A (zh) | 2017-02-22 |
US20170182129A1 (en) | 2017-06-29 |
WO2015150914A3 (en) | 2016-03-03 |
EP3125948A2 (en) | 2017-02-08 |
JP2017511334A (ja) | 2017-04-20 |
AU2015242354A1 (en) | 2016-11-10 |
WO2015150914A2 (en) | 2015-10-08 |
IL248009A0 (en) | 2016-11-30 |
KR20160137908A (ko) | 2016-12-01 |
CA2943751A1 (en) | 2015-10-08 |
EP3125948A4 (en) | 2017-11-15 |
BR112016022854A2 (pt) | 2018-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016012558A (es) | Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo. | |
NZ734019A (en) | Novel micro-dystrophins and related methods of use | |
MX2015014464A (es) | Vectores para terapia genica para tratar cardiomiopatía. | |
MX2016006774A (es) | Vectores de virus adeno-asociado para el tratamiento de la enfermedad de almacenamiento de glucogeno. | |
BR112018071167A2 (pt) | entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular | |
BR112019001887A2 (pt) | composições e métodos para o tratamento de doença associada a cep290 | |
CL2016000502A1 (es) | Vectores mejorados del factor viii del virus adeno-asociado de menos de 5,0 kb de longitud, que producen un polipéptido del factor viii funcionalmente activo para el tratamiento de la hemofilia a. | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
JP2018520646A5 (es) | ||
MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
NZ704275A (en) | Aav-mediated gene therapy for rpgr x-linked retinal degeneration | |
SG10201809075XA (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
IN2014DN06789A (es) | ||
MX2018007234A (es) | Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal. | |
WO2016057975A3 (en) | Guided injections for aav gene transfer to muscle | |
MX365711B (es) | Administración efectiva de genes grandes por vectores aav duales. | |
MY197586A (en) | Adenovirus armed with bispecific t cell engager (bite) | |
MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
EP4324845A3 (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
MX2016001204A (es) | Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo. | |
MX2022010959A (es) | Terapia genica para trastornos oculares. | |
MX2021009696A (es) | Vectores de genoterapia para el tratamiento de la enfermedad de danon. | |
MX2022016332A (es) | Administracion de vectores de virus adenoasociados para distrofias musculares. | |
EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы |